| High SEPT9_v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell Carcinoma. | |
| | |
MedLine Citation:
|
PMID: 20689765 Owner: NLM Status: PubMed-not-MEDLINE |
Abstract/OtherAbstract:
|
The purpose of this work was to determine SEPT9_v1 expression levels in head and neck squamous cell carcinoma (HNSCC) and to analyze whether SEPT9_v1 expression is relevant to clinical outcomes. Recently, the SEPT9 isoform SEPT9_v1 has been implicated in oncogenesis, and methylation of the SEPT9 promoter region was reported in HNSCC. These findings led us to hypothesize that SEPT9_v1 could be differently expressed in HNSCC. To determine whether SEPT9_v1 is expressed in HNSCC, tissue microarray immunohistochemical analysis was performed using a SEPT9_v1-specific antibody. Tissue microarrays stained with a polyclonal SEPT9_v1-specific antibody was used to determine protein expression levels in HNSCC tissue samples, some with known clinical outcomes. This analysis showed that SEPT9_v1 is in fact highly expressed in HNSCC compared with normal epithelium, and high expression levels directly correlated with poor clinical outcomes. Specifically, a high SEPT9_v1 expression was associated with decreased disease-specific survival (P = .012), time to indication of surgery at primary site (P = .008), response to induction chemotherapy (P = .0002), and response to chemotherapy (P = .02), as well as advanced tumor stage (P = .012) and N stage (P = .0014). The expression of SEPT9_v1 was also strongly correlated with smoking status (P = .00094). SEPT9_v1 is highly expressed in HNSCC, and a high expression of SEPT9_v1 is associated with poor clinical outcomes. These data indicate that SEPT9_v1 warrants additional investigation as a potential biomarker for HNSCC. |
| | |
Authors:
|
Laura Stanbery; Nisha J D'Silva; Julia S Lee; Carol R Bradford; Thomas E Carey; Mark E Prince; Gregory T Wolf; Francis P Worden; Kitrina G Cordell; Elizabeth M Petty |
Related Documents
:
|
16026875 - Kinetics of egfr expression during fractionated irradiation varies between different hu... 20485285 - Elevated xiap expression alone does not confer chemoresistance. 22649105 - Hes1 opposes a pten-dependent check on survival, differentiation, and proliferation of ... 19010635 - C-kit protein expression in wilms' tumour: an immunohistochemical study. 17473695 - Prognostic significance of the muc1 and muc4 expressions in thyroid papillary carcinoma. 10482545 - Induction of bcl-x(l) expression by human t-cell leukemia virus type 1 tax through nf-k... |
Publication Detail:
|
Type: Journal Article Date: 2010-08-01 |
Journal Detail:
|
Title: Translational oncology Volume: 3 ISSN: 1936-5233 ISO Abbreviation: Transl Oncol Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-08-06 Completed Date: 2011-07-14 Revised Date: 2012-05-03 |
Medline Journal Info:
|
Nlm Unique ID: 101472619 Medline TA: Transl Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 239-45 Citation Subset: - |
Affiliation:
|
The Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Grant Support | |
ID/Acronym/Agency:
|
R01 CA072877/CA/NCI NIH HHS |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian canc...
Next Document: Comparison of the side populations in pretreatment and postrelapse neuroblastoma cell lines.